Fulcrum Therapeutics (FULC) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Fulcrum Therapeutics (NASDAQ: FULC) recently:

• 12/13/2025 – Fulcrum Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/11/2025 – Fulcrum Therapeutics had its price target raised by analysts at Truist Financial Corporation from $14.00 to $18.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Fulcrum Therapeutics had its price target raised by analysts at Bank of America Corporation from $6.00 to $7.00. They now have an “underperform” rating on the stock.
• 12/8/2025 – Fulcrum Therapeutics was given a new $25.00 price target on by analysts at Stifel Nicolaus.
• 12/8/2025 – Fulcrum Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $15.00 to $24.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Fulcrum Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $7.00 to $10.00. They now have a “sector perform” rating on the stock.
• 12/8/2025 – Fulcrum Therapeutics had its “positive” rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
• 12/8/2025 – Fulcrum Therapeutics had its “underperform” rating reaffirmed by analysts at Citigroup Inc..
• 12/8/2025 – Fulcrum Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $23.00 price target on the stock, up previously from $16.00.
• 12/8/2025 – Fulcrum Therapeutics had its price target raised by analysts at HC Wainwright from $18.00 to $25.00. They now have a “buy” rating on the stock.
• 11/24/2025 – Fulcrum Therapeutics was given a new $14.00 price target on by analysts at Truist Financial Corporation.
• 11/24/2025 – Fulcrum Therapeutics had its price target raised by analysts at HC Wainwright from $12.00 to $18.00. They now have a “buy” rating on the stock.
• 11/24/2025 – Fulcrum Therapeutics is now covered by analysts at Truist Financial Corporation. They set a “buy” rating and a $14.00 price target on the stock.
• 11/1/2025 – Fulcrum Therapeutics was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 10/30/2025 – Fulcrum Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $16.00 price target on the stock, up previously from $12.50.
• 10/30/2025 – Fulcrum Therapeutics had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a “sector perform” rating on the stock.

Insider Transactions at Fulcrum Therapeutics

In related news, major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider directly owned 6,053,960 shares in the company, valued at approximately $84,634,360.80. The trade was a 40.82% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $11.03, for a total value of $165,450.00. Following the sale, the director directly owned 484,864 shares of the company’s stock, valued at $5,348,049.92. This represents a 3.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.00% of the stock is owned by corporate insiders.

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.